The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: An integrated model

被引：0
|
作者：
Dickinson, GL [1 ]
Lennard, MS [1 ]
Tucker, GT [1 ]
Rostami-Hodjegan, A [1 ]
机构：
[1] Univ Sheffield, Acad Unit Clin Pharmacol, Sheffield, S Yorkshire, England
来源：
DRUG METABOLISM REVIEWS | 2005年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
74
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [1] The propagation of genetic polymorphism in CYP2C9 into tolbutamide pharmacokinetics: Assessment using an integrated model
    Dickinson, Gemma L.
    Lennard, Martin S.
    Tucker, Geoffrey T.
    Rostami-Hodjegan, Amin
    DRUG METABOLISM REVIEWS, 2006, 38 : 148 - 148
  • [2] Association between CYP2C9 genetic polymorphism and warfarin treatment
    Ardicoglu, NY
    Tunca, A
    Adam, B
    Kargyly, A
    Koksal, V
    Karanfil, A
    CLINICA CHIMICA ACTA, 2005, 355 : S166 - S166
  • [3] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [4] Effects of CYP2C9 genetic polymorphism on the pharmacokinetics of zafirlukast.
    Kim, Mi-Jung
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E234 - E234
  • [5] CYP2C9 polymorphism and warfarin dose requirements
    Daly, AK
    Day, CP
    Aithal, GP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 408 - 409
  • [6] CYP2C9 polymorphism affects warfarin complications
    Reactions Weekly, 1999, 741 (1) : 4 - 4
  • [7] Genetic polymorphism of CYP2C9 and warfarin dose predicting in anticoagulation therapy
    Stefanovic, M
    Topic, E
    Samardzija, M
    CLINICAL CHEMISTRY, 2005, 51 : A151 - A151
  • [8] CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
    Chern, HD
    Ueng, TH
    Fu, YP
    Cheng, CW
    CLINICA CHIMICA ACTA, 2006, 367 (1-2) : 108 - 113
  • [9] Association between CYP2C9 polymorphism and warfarin dose
    Samardzija, M.
    Topic, E.
    Stefanovic, M.
    Zibar, L.
    Samardzija, G.
    Balen, S.
    Vcev, A.
    Domanovic, D.
    Barbic, J.
    Petrak, D.
    Sisljagic, V.
    BLOOD REVIEWS, 2007, 21 : S69 - S69
  • [10] The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements
    Kamali, F
    Khan, TI
    King, BP
    Frearson, R
    Kesteven, P
    Wood, P
    Daly, AK
    Wynne, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) : 668 - 668
12345